Cargando…
Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
Oncolytic virotherapies, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects. The OPTiM trial, in particular, demonstrated the superior anti-cancer effects of T-VEC as compared to systemic immunoth...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880985/ https://www.ncbi.nlm.nih.gov/pubmed/31774808 http://dx.doi.org/10.1371/journal.pcbi.1007495 |